Ossicodone HCl 80mg

Clinical Monograph: Oxycodone HCl 80 mg

Oxycodone HCl 80 mg extended-release packaging. Source: Taj Pharma India

1. Classification and Chemical Overview

Oxycodone is a semi-synthetic, pure opioid agonist derivative of the morphinan alkaloid thebaine. Chemically designated as (5$\alpha$)-4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride, it belongs to the phenanthrene class of opioids. Under the Anatomical Therapeutic Chemical (ATC) classification system, oxycodone is indexed under N02AA05.

Oxycodone HCl 80 mg is formulated as modified-release (prolonged-release / extended-release) oral tablets containing 80 mg oxycodone hydrochloride (equivalent to 71.72 mg free oxycodone base). Internationally, oxycodone is classified as a strictly controlled substance (e.g., Schedule II in the US; Class B / Schedule 2 Controlled Drug in the UK) and is available strictly as a Prescription Only Medicine (POM). The 80 mg single-tablet strength represents a high-dose unit intended solely for opioid-tolerant individuals.

2. Mechanism of Action and Pharmacodynamics

Oxycodone acts as a full agonist at central and peripheral opioid receptors, displaying primary selectivity for $\mu$-opioid receptors alongside minor interactions at $\kappa$– and $\delta$-opioid receptors:

• $\mu$-Opioid Receptor Activation: Binds to G-protein-coupled $\mu$-receptors located on presynaptic and postsynaptic neuronal membranes throughout the central nervous system (brainstem, locus coeruleus, periaqueductal gray) and spinal cord (dorsal horn).

• Signal Transduction: Inhibits adenylyl cyclase activity, decreases intracellular cyclic AMP ($\text{cAMP}$), hyperpolarizes neuronal membranes by opening inwardly rectifying potassium channels, and inhibits voltage-gated calcium channels.

• Analgesic Transmission: Suppresses presynaptic release of nociceptive neurotransmitters (substance P, glutamate, CGRP), attenuating pain impulse conduction along spinothalamic pathways and modifying central perception of pain.

Additional systemic pharmacodynamic actions include dose-dependent respiratory center depression, sedation, miosis, cough suppression, gastrointestinal smooth muscle tone elevation (leading to delayed transit), and biliary sphincter spasm.

3. Approved Clinical Indications and Therapeutic Scope

Licensing for Oxycodone HCl 80 mg includes:

• Severe Chronic Pain Management: Management of severe, refractory pain requiring continuous, round-the-clock opioid administration for an extended period (e.g., advanced cancer-related pain or severe chronic non-cancer pain unresponsive to lower opioid dosages).

Formulation Dynamics & Dosing Regimens:

• Modified-Release / Prolonged-Release (MR) 80 mg: Formulated for continuous 12-hour drug delivery. Administered twice daily (every 12 hours) for stable chronic pain control.

• Strict Safety Mandate: Modified-release 80 mg tablets must be swallowed whole and never crushed, chewed, split, or dissolved. Disrupting the controlled-release delivery matrix causes rapid drug release (“dose dumping”), leading to acute toxicity, massive overdose, respiratory arrest, and death.

4. Pharmacokinetic Profile and Metabolic Fate

• Absorption: Extended-release matrices provide continuous, slow absorption over 12 hours. Absolute oral bioavailability is high (60% to 87%) due to low hepatic first-pass metabolism. Peak plasma concentration (Cmax​) occurs within 3 to 5 hours (Tmax​) post-ingestion.

• Distribution: Extensively distributed throughout body tissues following systemic uptake (Vd​≈2.6 L/kg). Plasma protein binding ranges between 38% and 45% (primarily to human serum albumin). Oxycodone crosses the blood-brain barrier and placenta, and is excreted in human breast milk.

• Biotransformation: Extensively metabolised in the liver via two primary Cytochrome P450 pathways:

  • CYP3A4 Pathway (Major): $N$-demethylation to noroxycodone (inactive/weakly active circulating metabolite).

  • CYP2D6 Pathway (Minor): $O$-demethylation to oxymorphone (potent active opioid agonist).

  • Metabolites undergo subsequent Phase II glucuronide conjugation.

• Elimination: Excreted predominantly via the kidneys in urine as conjugated metabolites and unchanged parent compound (< 10%). Elimination half-life (t1/2​) is approximately 8 hours for modified-release formulations.

5. Physiological Effects and Adverse Event Spectrum

Oxycodone depresses central nervous system processing and slows peripheral gastrointestinal motility.

Adverse Drug Reaction Spectrum

• Very Common ($\ge 1/10$): Constipation, nausea, vomiting, somnolence, dizziness, headache, pruritus.

• Common ($\ge 1/100$ to $<1/10$): Dry mouth, anorexia, abdominal pain, dyspepsia, asthenia/fatigue, confusion, anxiety, depression, insomnia, hyperhidrosis, rash.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Respiratory depression, profound sedation, miosis, urinary retention, hallucinations, agitation, euphoria, orthostatic hypotension, physical dependence/withdrawal symptoms.

• Rare / Very Rare (<1/1,000): Anaphylactic reactions, paralytic ileus, seizures, opioid-induced hyperalgesia, adrenal insufficiency.

6. Contraindications, Drug Interactions, and Clinical Precautions

Controindicazioni

• Opioid-Naïve Patients: Absolutely contraindicated in non-opioid-tolerant individuals. Administering an 80 mg single dose to an opioid-naïve patient can precipitate severe, fatal respiratory depression.

• Known hypersensitivity to oxycodone or formulation excipients.

• Severe respiratory depression with hypoxia or hypercapnia.

• Severe chronic obstructive pulmonary disease (COPD) or acute severe bronchial asthma.

• Paralytic ileus or acute abdomen.

• Moderate to severe hepatic impairment.

Key Drug Interactions

• CYP3A4 Inhibitors (e.g., Ketoconazole, Clarithromycin, Ritonavir, Grapefruit Juice): Significantly increase plasma oxycodone concentrations, drastically elevating the risk of fatal respiratory depression.

• CYP3A4 Inducers (e.g., Rifampicin, Carbamazepine, St. John’s Wort): Accelerate clearance, reducing efficacy and potentially precipitating withdrawal in dependent patients.

• CNS Depressants, Benzodiazepines, & Alcohol: Co-administration markedly increases the risk of profound sedation, life-threatening respiratory depression, coma, and fatal overdose.

• Monoamine Oxidase Inhibitors (MAOIs): Caution is required; co-administration may precipitate severe CNS excitation or depression.

Clinical Precautions and Monitoring

• Strict Opioid Tolerance Definition: Patients are considered opioid-tolerant only if they have been taking at least 60 mg oral morphine daily, 30 mg oral oxycodone daily, 8 mg oral hydromorphone daily, or an equianalgesic dose of another opioid for one week or longer.

• Risk of Addiction, Misuse, and Abuse: Oxycodone 80 mg carries a substantial risk of opioid use disorder, dependence, and diversion.

• Tolerance & Tapering: Extended usage induces physical dependence. Abrupt discontinuation of an 80 mg regimen triggers severe withdrawal symptoms (agitation, lacrimation, diaphoresis, chills, myalgia, severe abdominal cramps). Dosage must be gradually tapered when discontinuing treatment.